Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Bioorg Med Chem Lett. 2011 Oct 5;21(23):6973–6976. doi: 10.1016/j.bmcl.2011.09.123

Table 1.

Antibacterial activities of compounds 1, 2, 10, 15, 16 and 21–27.a graphic file with name nihms334357u1.jpg

Compound R R1 Gram (+)
Gram (−)
B. anthracis E. faecalis S. aureus (MSSA) S. aureus (MRSA) M. tuberculosis (H37Rv) Acineto-bacter E. coli k12 E. coli tolc
Fosmidomycin (1) H H/Nab 0.78 >200 >200 200 >500 100 12.5 6.25
FR900098 (2) CH3 H/Nab 50 >200 >200 50 >500 50 200 12.5
10 H Et >200 >200 >200 >200 400 >200 >200 >200
15 CH3 Et 200 >200 >200 200 200–400 >200 >200 >200
16 CH3 iPr >200 >200 >200 >200 400 >200 >200 >200
21 CH3 graphic file with name nihms334357t1.jpg NDc ND ND ND 100 ND ND ND
22 CH3 graphic file with name nihms334357t2.jpg >200 >200 >200 >200 400 >200 >200 200
23 CH3 graphic file with name nihms334357t3.jpg >200 >200 100 25 400 >200 >200 >200
24 CH3 graphic file with name nihms334357t4.jpg 200 >200 100 50 50–100 >200 >200 100
25 CH3 graphic file with name nihms334357t5.jpg 200 >200 100 50 400 >200 >200 >200
26 CH3 graphic file with name nihms334357t6.jpg 100 >200 >200 >200 25–100 200 >200 50
27 CH3 graphic file with name nihms334357t7.jpg 50 >200 >200 >200 100–200 100 50 50
a

Minimum Inhibitory Concentrations (MIC) in μg/mL.

b

Compounds 1 and 2 used as the monosodium salts.

c

ND = not determined.